UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Behandlung der Acne fulminans mit Tumornekrosefaktor‐α‐Inhibitoren – eine Übersicht klinischer Fälle und der Literatur

Journal der Deutschen Dermatologischen Gesellschaft, 2024-01, Vol.22 (1), p.23-28

2024

Volltextzugriff (PDF)

Leishmaniasis in immunosuppressed individuals

Clinical microbiology and infection, 2014-04, Vol.20 (4), p.286-299

2014

Volltextzugriff (PDF)

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

Inflammatory bowel diseases, 2011-09, Vol.17 (9), p.1846-1854

2011

Volltextzugriff (PDF)

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Journal of the American Academy of Dermatology, 2020-05, Vol.82 (5), p.1094-1101

2020

Volltextzugriff (PDF)

Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment

Journal of pediatric gastroenterology and nutrition, 2023-05, Vol.76 (5), p.576-581

2023

Volltextzugriff (PDF)

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Volltextzugriff (PDF)

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Enfermedades infecciosas y microbiologia clinica (English ed.), 2024-02, Vol.42 (2), p.98-101

2024

Volltextzugriff (PDF)

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

World journal of gastroenterology : WJG, 2009-05, Vol.15 (17), p.2067-2073

2009

Volltextzugriff (PDF)

Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy

Gastroenterología y hepatología, 2024-09, p.502252, Article 502252

2024

Volltextzugriff (PDF)

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease

Clinical gastroenterology and hepatology, 2024-01

2024

Volltextzugriff (PDF)

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

Frontiers in immunology, 2019-03, Vol.10, p.382-382

2019

Volltextzugriff (PDF)

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review

Clinical gastroenterology and hepatology, 2020-02, Vol.18 (2), p.304-312

2020

Volltextzugriff (PDF)

TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)

Journal of allergy and clinical immunology, 2022-05, Vol.149 (5), p.1812-1816.e6

2022

Volltextzugriff (PDF)

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

Journal of rheumatology, 2018-08, Vol.45 (8), p.1167-1172

2018

Volltextzugriff (PDF)

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

British journal of clinical pharmacology, 2024-01, Vol.90 (1), p.189-199

2024

Volltextzugriff (PDF)

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Osteoarthritis and cartilage, 2018-07, Vol.26 (7), p.880-887

2018

Volltextzugriff (PDF)

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

Digestive and liver disease, 2024-07

2024

Volltextzugriff (PDF)

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

Cytokine (Philadelphia, Pa.), 2018-01, Vol.101, p.56-63

2018

Volltextzugriff (PDF)

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Journal of clinical pharmacology, 2024-04, Vol.64 (4), p.418-427

2024

Volltextzugriff (PDF)

Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD

Gastroenterología y hepatología, 2024-09, p.502258, Article 502258

2024

Volltextzugriff (PDF)

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Enfermedades infecciosas y microbiología clínica, 2024-02, Vol.42 (2), p.98-101

2024

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Trajectory of body mass index and obesity in children with Crohn's disease compared to healthy children

Journal of pediatric gastroenterology and nutrition, 2024-01, Vol.78 (1), p.85-94

2024

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.266-276.e5

2018

Volltextzugriff (PDF)

Role of the IL23/IL17 Pathway in Crohn's Disease

Frontiers in immunology, 2021-03, Vol.12, p.622934

2021

Volltextzugriff (PDF)

1 – 25 von 3.872

Suche als RSS-Feed

Aktive Filter

SpracheFranzösisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.526)
Mit Volltextzugriff
(3.036)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(3.077)
Life Sciences & Biomedicine
(3.058)
Humans
(2.240)
Anti-Tnf
(1.346)
Female
(1.233)
Male
(1.177)
Tumor Necrosis Factor-Alpha - Antagonists & Inhibitors
(1.147)
Rheumatology
(1.005)
Adult
(933)
Middle Aged
(907)
Infliximab
(861)
Rheumatoid Arthritis
(845)
Gastroenterology & Hepatology
(711)
Treatment Outcome
(688)
Adalimumab
(684)
Inflammatory Bowel Disease
(628)
Antirheumatic Agents - Therapeutic Use
(570)
Arthritis, Rheumatoid - Drug Therapy
(552)
Antibodies, Monoclonal - Therapeutic Use
(528)
Crohn's Disease
(496)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(2.332)
Ingenta
(1.885)
EZB Electronic Journals Library
(1.480)
Journals@Ovid Full Text
(1.401)
Elsevier ScienceDirect Journals Complete
(781)
IngentaConnect Journals
(687)
Springer Journals
(552)
Oxford journals
(478)
Taylor & Francis Journals
(469)
Wiley Online Library
(434)
Taylor & Francis
(431)
Oxford Journals 2020 Medicine
(407)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(354)
Taylor & Francis Online
(323)
Publisher or Other Site
(264)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(242)
Wiley Online Library Full Collection 2018
(223)
BMJ Journals
(194)
BMJ Journals Archiv - DFG Nationallizenzen
(156)
SAGE Journals
(96)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Behandlung der Acne fulminans mit Tumornekrosefaktor‐α‐Inhibitoren – eine Übersicht klinischer Fälle und der Literatur

Leishmaniasis in immunosuppressed individuals

Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease

Increased arterial stiffness in Crohn's disease: Prevalence, associated factors and impact of anti-TNF therapy

Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease

Anti-TNF Therapy in Spondyloarthritis and Related Diseases, Impact on the Immune System and Prediction of Treatment Responses

Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review

TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency (DADA2)

Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

A first‐in‐human study of the novel immunology antibody–drug conjugate, ABBV‐3373, in healthy participants

A randomised double-blind placebo-controlled crossover trial of HUMira (adalimumab) for erosive hand OsteoaRthritis – the HUMOR trial

Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: Real-world data from a nationwide study

Molecular mechanisms of action of anti-TNF-α agents – Comparison among therapeutic TNF-α antagonists

Population Pharmacokinetics of Ozoralizumab in Patients with Rheumatoid Arthritis

Antiphospholipid syndrome autoantibodies induction after treatment with anti-TNF alpha therapy in patients with IBD

Disseminated tuberculosis after anti-TNF alpha treatment: Do not blindly trust the IGRA test

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Trajectory of body mass index and obesity in children with Crohn's disease compared to healthy children

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT)

Role of the IL23/IL17 Pathway in Crohn's Disease

Aktive Filter

Suchergebnisse filtern